Galedra
Sign in Sign up

Claims

As of snapshot 27745 under ledger-default@0.3.0.

ClaimTypeAssessmentScoreReview checksReferences
In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve symptoms, six-minute walk distance, or secondary endpoints versus placebo, although safety was generally similar. QUANTITATIVE Supported 0.9908 1 of 4 120